Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Novartis posts eye drug data amid play for Eylea's turf

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 11:42pm CEST
Swiss drugmaker Novartis' logo is seen in Stein

ZURICH (Reuters) - Novartis's (>> Novartis) bid to move in on Bayer's (>> Bayer) and Regeneron's (>> Regeneron Pharmaceuticals) eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

ZURICH (Reuters) - Novartis's (>> Novartis) bid to move in on Bayer's (>> Bayer) and Regeneron's (>> Regeneron Pharmaceuticals) eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Active disease was observed in 23.5 percent of RTH258 patients versus 33.5 percent of Eylea patients at 16 weeks, Novartis said, of its investigational treatment for wet age-related macular degeneration (AMD), where abnormal, leaky blood vessels can cause blindness.

A second, similar study found active disease in 21.9 percent of RTH258 patients versus 31.4 percent of those on Eylea for the condition affecting 20-25 million people worldwide.

Novartis in June touted initial data showing its drug may require fewer injections directly into the eye than Eylea, while matching it on vision and safety measures.

The Basel-based drugmaker hopes this latest analysis lends RTH258 additional muscle when matched head-to-head with Eylea as well as Lucentis, which Roche (>> Roche Holding Ltd.) sells in the United States.

"When you take all of that together ... we believe we have a very compelling proposition," Vas Narasimhan, Novartis's chief drug developer who will become CEO in 2018, said on a conference call.

Novartis, which released the data at the American Academy of Opthalmology conference in New Orleans, predicts RTH258 annual sales will top $1 billion and aims to file for U.S. approval in late 2018.

Making it a success is by no means clear sailing.

For one, Novartis owns Lucentis rights in Europe where it has contractual obligations to continue marketing that drug. Analysts say cannibalization from RTH258 will be a challenge.

Competition abounds, too: Eylea, with $5 billion in annual sales, has made inroads against the $3.2 billion-per-year Lucentis, whose 2020 U.S. patent expiration will expose it to cheaper copies.

Moreover, Roche's cancer drug Avastin is effective in off-label AMD use and has won favour because it costs a fraction of Lucentis and Eylea. In Britain, Novartis and Bayer are fighting doctor groups aiming to switch to Avastin.

NEEDLE IN THE EYE

Other would-be rivals are racing to market, too.

Allergan (>> Allergan plc), whose investigational Abicipar is in Phase III trials, is also trumpeting prospects of reduced injections compared to Lucentis. Gene therapies may also be on the distant horizon.

Still, Novartis's Narasimhan remains optimistic for RTH258's reception when it hits the market, likely in 2019.

"When you actually see an image of a patient having a needle inserted into their eye, this is something patients definitely want to avoid," he said.

"Retinal surgeons have busy offices and want to do more complex retinal surgery. Today, they have offices filled with patients waiting for injections."

(Reporting by John Miller; Editing by Adrian Croft)

By John Miller

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC -0.62% 191.31 Delayed Quote.16.95%
BAYER -0.67% 76.01 Delayed Quote.-25.23%
MOLECULAR PARTNERS AG -0.45% 22.1 Delayed Quote.-15.59%
NOVARTIS -0.46% 81.48 Delayed Quote.-0.63%
REGENERON PHARMACEUTICALS 0.78% 390.28 Delayed Quote.3.81%
ROCHE HOLDING LTD. -0.81% 233.15 Delayed Quote.-4.60%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
09/20ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
AQ
09/20ALLERGAN : Unveils Spotlyte™, A First-In-Category Digital Hub Designed To ..
AQ
09/20ALLERGAN : to Host Medical Aesthetics Day Event on September 14, 2018
AQ
09/20ALLERGAN : Study Results from Allergan Update Understanding of Acute Kidney Inju..
AQ
09/20ALLERGAN : Teams Up with Actor Scott Eastwood to Encourage Recognition of World ..
PR
09/20ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic (onabotulinumtoxinA) ..
AQ
09/19ALLERGAN : Announces Plans to Build First Medical Aesthetics Innovation Center i..
PU
09/19ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic for the Treatment of ..
AQ
09/19ALLERGAN : Highlights Key Growth Drivers for Medical Aesthetics
AQ
09/19SOSEI : Allergan to delay trials of dementia candidate
AQ
More news
News from SeekingAlpha
09/18Allergan Snaps Up Early Stage Startup, Goes Back To Its Aesthetic Roots 
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
09/18Senate passes opioid crisis bill 
09/17House nixes drug prices in TV ads 
09/14Allergan's Botox shows treatment benefit at higher doses 
Financials ($)
Sales 2018 15 523 M
EBIT 2018 7 411 M
Net income 2018 -1 186 M
Debt 2018 23 063 M
Yield 2018 1,45%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,67x
EV / Sales 2019 5,43x
Capitalization 64 939 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 212 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC16.95%64 939
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY26.36%189 092